Don't Think of Corlanor as a Replacement for Beta-Blockers for Heart Failure

Corlanor (CORE-lah-nore, ivabradine) will be the first new drug approved for systolic heart failure in a decade.

It works by inhibiting the If or "funny" current in the sinoatrial node. This lowers heart rate...withOUT causing a drop in blood pressure.

Ivabradine prevents 1 in 25 patients from being hospitalized over 2 years...when ADDED to an ACEI or ARB, beta-blocker, and aldosterone antagonist. But it DOESN'T reduce overall mortality.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote